Cytonus Therapeutics Cargocyte Platform for Delivery of Oncolytic Viruses to be Highlighted at the ASGCT Annual Meeting

Editorial & Advertiser Disclosure Global Banking And Finance Review is an independent publisher which offers News, information, Analysis, Opinion, Press Releases, Reviews, Research reports covering various economies, industries, products, services and companies. The content available on is sourced by a mixture of different methods which is not limited to content produced and supplied by various staff writers, journalists, freelancers, individuals, organizations, companies, PR agencies Sponsored Posts etc. The information available on this website is purely for educational and informational purposes only. We cannot guarantee the accuracy or applicability of any of the information provided at with respect to your individual or personal circumstances. Please seek professional advice from a qualified professional before making any financial decisions. also links to various third party websites and we cannot guarantee the accuracy or applicability of the information provided by third party websites. Links from various articles on our site to third party websites are a mixture of non-sponsored links and sponsored links. Only a very small fraction of the links which point to external websites are affiliate links. Some of the links which you may click on our website may link to various products and services from our partners who may compensate us if you buy a service or product or fill a form or install an app. This will not incur additional cost to you. A very few articles on our website are sponsored posts or paid advertorials. These are marked as sponsored posts at the bottom of each post. For avoidance of any doubts and to make it easier for you to differentiate sponsored or non-sponsored articles or links, you may consider all articles on our site or all links to external websites as sponsored . Please note that some of the services or products which we talk about carry a high level of risk and may not be suitable for everyone. These may be complex services or products and we request the readers to consider this purely from an educational standpoint. The information provided on this website is general in nature. Global Banking & Finance Review expressly disclaims any liability without any limitation which may arise directly or indirectly from the use of such information.

Cytonus Therapeutics Inc., a biotechnology company developing new platforms for delivering biologics, announced today that it will be presenting preclinical data for its Cargocyte„¢ technology platform at the American Society of Gene and Cell Therapy (ASGCT) annual meeting April 29 “ May 2 in Washington, DC.

We are excited to be presenting our preclinical data supporting Cargocytes„¢, a first-of-its-kind, cell-based platform technology for delivery of an Oncolytic Virus into metastatic tumors, said Remo Moomiaie-Qajar, M.D., president and CEO of Cytonus. Our technology unleashes the promise of using Oncolytic Viruses to treat solid tumors by addressing a number of critical problems they inherently have, mainly homing the viruses to specific tissue without the immune system destroying it and then delivering those viruses into tumor cells. In addition, we are proud of our growing immune-oncology work with our Cargocytes and look forward to sharing our data at this years ASGCT meeting.

Cargocytes are engineered allogenic cell lines that can carry a variety of payloads like small molecule compounds, gene editing therapies, therapeutic RNAs, and powerful biologics such as immune modulating cytokines, antibodies and oncolytic viruses.

Details of the presentations:

Abstract Title: Cargocyte„¢ Biofactories: A New Versatile Cell Therapy Platform for Delivery of a Wide Range of Biologics

Session Date/Time: Monday Apr 29, 2019 5:00 PM – 6:00 PM Session title: Cancer-Targeted Gene & Cell Therapy Room: Columbia Hall Final abstract number: 272

Abstract Title: Cargocyte„¢ Biofactories: A Novel Platform for Delivering Oncolytic Viruses to Treat Metastatic Cancer

Session Date/Time: Tuesday Apr 30, 2019 3:30 PM – 5:15 PM Session title: Oncolytic Viruses II Room: International Ballroom Our Presentation Time: 4:00 PM – 4:15 PM Final abstract number: 404

Abstract Title: Cargocytes„¢: A Novel Cell Therapy Platform to Drive Anti-Tumor Immunity

Session Date/Time: Tuesday Apr 30, 2019 5:00 PM “ 6:00 PM Session title: Cancer-Immunotherapy, Cancer Vaccines Room: Columbia Hall Final abstract number: 578

Cytonus will also be presenting at the Bio International Convention, June 3-6, 2019 in Philadelphia.

Cytonus Therapeutics Inc.

Cytonus Therapeutics Inc. is a biopharmaceutical company developing a next-generation Adoptive Cellular Transport platform called Cargocytes„¢. The San Diego-based companys proprietary Cargocyte„¢ platform are cellular-engineered transporters of a multiplicity of therapeutic payloads to tissue in a selective, controllable and potent off-the-shelf cellular therapy for the potential treatment of several diseases across multiple therapeutic areas. Cytonus initial focus is to advance Cargocyte„¢ candidates for the treatment of rare and difficult to treat cancers and inflammatory diseases. For more information, visit or follow us on LinkedIn.

Statements in this news release, which relate to other than strictly historical facts, such as statements about Cytonus plans and strategies, new and existing products and technologies, anticipated clinical and regulatory pathways, and markets for its products are forward-looking statements. The words “believe,” “expect,” “anticipate,” “estimate,” “project,” and similar expressions identify forward-looking statements that speak only as of the date hereof. Such statements involve risks and uncertainties that could cause actual results to differ materially from anticipated results due to many factors, including regulatory and development risks. Cytonus undertakes no obligation to publicly update or revise any forward-looking statements. This news release is neither an offer to sell, nor the solicitation of any offer to purchase, any security.

Henry Gillespie
[email protected]